Jun Zhang, MD, PhD
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Jun Zhang, MD, PhD sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Jun Zhang, MD, PhD: 3 sponsored US clinical trials, 2 recruiting.
Jun Zhang, MD, PhD sponsors 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is NSCLC, Stage III, with 1 trials.
Upper-quartile sponsor footprint
Jun Zhang, MD, PhD sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
NCT05332925
Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients
NCT04680377
A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
NCT05859217
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Therapeutic Areas
What is open in the Jun Zhang, MD, PhD pipeline
2 recruiting of 3 indexed (67% open).
Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).
Top condition: NSCLC, Stage III (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Jun Zhang, MD, PhD: open-pipeline peers nationwide
Peers matched on 3 registered trials and 67% open enrollment, not the therapeutic-area sidebar.
Jun Zhang, MD, PhD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 67% open enrollment (± trial volume)
- Abbisko Therapeutics Co · 67% recruiting · 6 trials
- ABL Bio · 67% recruiting · 3 trials
- Accelerated Cure Project for Multiple Sclerosis · 67% recruiting · 3 trials
- Advanced Reconstructive Surgery Alliance · 67% recruiting · 3 trials
Related
What to do with this Jun Zhang, MD, PhD page
3 registered trials is a research-attention snapshot, not an endorsement of Jun Zhang, MD, PhD or any single study.
- 2 of Jun Zhang, MD, PhD's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- NSCLC, Stage III is the condition Jun Zhang, MD, PhD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See NSCLC, Stage III trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Jun Zhang, MD, PhD pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.